larry luv

Buy Shares of Imaging3 in Anticipation of Future FDA Approval

MY Typo -You said 263 million O/S. That is incorrect.
400 MILLION is more like it

Buy Shares of Imaging3 in Anticipation of Future FDA Approval

There was a recent Private Placement finalized for over 100mil shares.Your O/S Comment of 260,000 is disingenuius.
total-It is around 400 million+ O/S now.
The CEO Dean Janes has said the only remaining questions the FDA had was the labeling/intended use issue.
Now the fact that the FDA is still inquiring to IMGG about how they labeled their intended uses for the Dominion obviously means there are some issues that the FDA was not agreeable in approving this Device under IMGG's prior submission of labeling/intended use.
Dean Janes is now saying that issue is resolved but its not up to him,its up to the FDA to approve this recent resubmission by IMGG.
This FDA approval is NOT a slam dunk yet' as many would have you believe.
There has been hundreds of CEO's that have been confident that their drug or device would be approved,only to have the FDA give them a Black Eye...
The Dominion may get approval,but this overconfidence is a negative..

Chembio Diagnostics: A buyer's delight

Great read and a quick thorough synopsis of the Company and its potential.
Im all in! Thanks..

Medasorb: Investors need to absorb the potential

Forget about Betasorb in the future US market.That will be tough'
Nephros's H2h/MD220 FILTER will be direct competition. as it does what Betasorb filter claims to do..
Nephros is awaiting US approval for their filter any day now and Betasorb would be a few years away.Also,Nephros will corner the Euopean market too as they are already approved in Europe with their blood filters for kidney dialysis patients..
The Medasorb is the best shot,Nephros is not currently in that Sepsis Maket.
NEPh is the safe play now.MSBT has a future shot..

Nephros Continues to Rise Ahead of FDA Decisions

Buzz on the Message boards is Why has Nephros not put out PR on their USA clinical trial for the 2 pending devices up for FDA approval.
If good clinical results,WHY no News?

Hemispherx's Ampligen: Fact vs. Fiction

Michael,or Nick'
please fill me in about positive results of clinical trial for Ampligen based on just a stamina treadmill study...
What am I missing here please?

Hemispherx's Ampligen: Fact vs. Fiction

Are we just going by results of a treadmill clinical trial for possible approval of this drug? thats all? The FDA has agreed that no other types of CFS studies should occur?
What about clinical trials for sleep patterns and muscle weakness in CFS patients? Im perplexed that based on friggin' treadmill results, the FDA would approve Ampligen for sale...Am I missing something here?A study based on treadmill stamina,thats it?
Someone fill me in please...
?

Big Pharma: Where's the Risk Management?

There is a need for a non injectable,but there is absolutely no proof
that Oral-Lyn works.
IF oral-lyn works,believe me,Generex would have put out a BIG press release years ago since it has been approved in Ecuador,
You dont hear a peep from management. about the use in Ecuador,its been 4 years and counting.
Case closed//

Antigenics: The Big Boys Are Buying

VFC'
There has been some buzz on the AGEN yahoo board that Antigenics lost some patent rights to QS-21 last May and October of 2008 and 2 other remaining QS-21 patents expire in a few years.
So my question is what happens to Antigentics licensing deals they have with other Pharmas that are using QS-21 in clinical trials?
And how will /does that effect any potential milestone and royalty fees if/when Antigenics no longer lay claim to QS-21 as their own?
.

Sirius XM's iPhone App Stats Are Misleading

This is not' the first time short interest data has shown a decrease,only to see Sirius stock decrease more.
I am not impressed by this recent short interest descrease,it is still WAY too high.It's not like all the shorts went home with their tails wagging behind them
Sirius XM needs to prove its investor worth before this doo doo stock' turns the corner and becomes a golden nugget'

Big Pharma: Where's the Risk Management?

Followup
Have you done your due dilegece of Oral-Lyn in Ecuador and India?
Do you come up with any positives that I am unaware of?
I hope so. please do tell.. thank you

Big Pharma: Where's the Risk Management?

Sir,you artiulate well in your blog however let's get to the brass tax of things..
Oral-Lyn has been marketed in Ecuador for 4 years now 4 years..
You do not hear a peep out of Generex pertaining to sales-revenues and efficacy. Now lets get to India,where it has been reported that at least 1/3 of the worlds population of diabetis live in India.
Oral-Lyn renamed in India Oral-Recosulin was halted from sales due to regulatory isues,as no human clinical trials were conducted in that country.
Also prior to the halt of Oral-Lyn in India,there were ONLY 100 orders in the whole country' Please Sir' before you go praising Generex,what do you have in response to my comments?
How can anyone expect an FDA approval of Oral-Lyn if its already failing in Ecuador And India?
thank you//

Look Ahead to Sirius XM's Q2 Numbers

Satellite was discussed..It was all over the message boards and some articles written..

Discovery Laboratories is a BUY here, not a sell!

Where do you come up with DSCO has enough cash to last 2 years?
Absolutely a fallacy Sir.
Maybe 6-12mths tops..
They need a buyout and new mgmt.

Is Sirius XM Facing a Nasdaq Delisting?

Sir, WHY would you post an article like that heading at this juncture?Sirius XM is getting positive feedback from outside sources,New Satellite about to be launched today and now this?
Is Sirius XM FACING NASDAQ DELISTING?
I dont care what spin you gave in the actual article..
The heading says it all, SHAMEFUL.